A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006)

A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006)

(Abstracted from J Clin Oncol 2022;41:276–284 Complete resection of macroscopic disease remains a key focus of cytoreductive surgery for the treatment of ovarian cancer. Barriers to achieving complete resection include small-sized lesions, obscuring tissue damage from prior chemotherapy, and incompl...

Full description

Saved in:
Bibliographic Details
Published in:Obstetrical & gynecological survey Vol. 78; no. 6; pp. 341 - 342
Main Authors: Tanyi, Janos L., Randall, Leslie M., Chambers, Setsuko K., Butler, Kristina A., Winer, Ira S., Langstraat, Carrie L., Han, Ernest S., Vahrmeijer, Alexander L., Chon, Hye Sook, Morgan, Mark A., Powell, Matthew A., Tseng, Jill H., Lopez, Alexis S., Wenham, Robert M.
Format: Journal Article
Language:English
Published: Lippincott Williams & Wilkins 01-06-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:(Abstracted from J Clin Oncol 2022;41:276–284 Complete resection of macroscopic disease remains a key focus of cytoreductive surgery for the treatment of ovarian cancer. Barriers to achieving complete resection include small-sized lesions, obscuring tissue damage from prior chemotherapy, and incomplete exploration.
ISSN:0029-7828
1533-9866
DOI:10.1097/01.ogx.0000943176.03306.5b